These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

148 related items for PubMed ID: 27612035

  • 1. Should we stop offering indium-111 octreotide scans in favour of gallium-68 PET-CT scans in the UK?
    Kalsy N, Vinjamuri S.
    Nucl Med Commun; 2016 Dec; 37(12):1221-1222. PubMed ID: 27612035
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Influence of PET/CT 68Ga somatostatin receptor imaging on proceeding with patients, who were previously diagnosed with 99mTc-EDDA/HYNIC-TOC SPECT.
    Madrzak D, Mikołajczak R, Kamiński G.
    Nucl Med Rev Cent East Eur; 2016 Dec; 19(2):88-92. PubMed ID: 27479886
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Gallium-68-dotatate PET/CT is better than CT in the management of somatostatin expressing tumors: First experience in Africa.
    Lawal IO, Ololade KO, Lengana T, Reyneke F, Ankrah AO, Ebenhan T, Vorster M, Sathekge MM.
    Hell J Nucl Med; 2017 Dec; 20(2):128-133. PubMed ID: 28697189
    [Abstract] [Full Text] [Related]

  • 6. Observation on enhanced avidity on somatostatin receptor targeted 68Ga-DOTATATE PET-CT following therapy with everolimus and capecitabine-temozolamide: is redifferentiation akin phenomenon a reality in neuroendocrine tumors?
    Basu S, Ostwal V.
    Nucl Med Commun; 2016 Jun; 37(6):669-71. PubMed ID: 27105440
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Patient selection for personalized peptide receptor radionuclide therapy using Ga-68 somatostatin receptor PET/CT.
    Kulkarni HR, Baum RP.
    PET Clin; 2014 Jan; 9(1):83-90. PubMed ID: 25029937
    [Abstract] [Full Text] [Related]

  • 9. Comparison of 68Ga-DOTANOC and 68Ga-DOTATATE PET/CT within patients with gastroenteropancreatic neuroendocrine tumors.
    Wild D, Bomanji JB, Benkert P, Maecke H, Ell PJ, Reubi JC, Caplin ME.
    J Nucl Med; 2013 Mar; 54(3):364-72. PubMed ID: 23297077
    [Abstract] [Full Text] [Related]

  • 10. Head-to-Head Comparison of 64Cu-DOTATATE and 68Ga-DOTATOC PET/CT: A Prospective Study of 59 Patients with Neuroendocrine Tumors.
    Johnbeck CB, Knigge U, Loft A, Berthelsen AK, Mortensen J, Oturai P, Langer SW, Elema DR, Kjaer A.
    J Nucl Med; 2017 Mar; 58(3):451-457. PubMed ID: 27660147
    [Abstract] [Full Text] [Related]

  • 11. Fibromatosis mimicking relapse of a neuroendocrine tumor at 68Ga-DOTATOC positron-emission tomography/computed tomography.
    Trevisi E, Facilissimo I, Taraglio S, Brizzi MP.
    J Cancer Res Ther; 2022 Mar; 18(4):1171-1173. PubMed ID: 36149180
    [Abstract] [Full Text] [Related]

  • 12. Current knowledge on the sensitivity of the (68)Ga-somatostatin receptor positron emission tomography and the SUVmax reference range for management of pancreatic neuroendocrine tumours.
    Virgolini I, Gabriel M, Kroiss A, von Guggenberg E, Prommegger R, Warwitz B, Nilica B, Roig LG, Rodrigues M, Uprimny C.
    Eur J Nucl Med Mol Imaging; 2016 Oct; 43(11):2072-83. PubMed ID: 27174220
    [Abstract] [Full Text] [Related]

  • 13. Radio-guided surgery in neuroendocrine tumors.
    Gulec SA, Baum R.
    J Surg Oncol; 2007 Sep 15; 96(4):309-15. PubMed ID: 17726664
    [Abstract] [Full Text] [Related]

  • 14. What will be required to bring ⁶⁸Ga-labelled peptides into routine clinical use?
    Ballinger JR, Solanki KK.
    Nucl Med Commun; 2011 Dec 15; 32(12):1109-12. PubMed ID: 21934542
    [No Abstract] [Full Text] [Related]

  • 15. Diagnostic performance of Gallium-68 somatostatin receptor PET and PET/CT in patients with thoracic and gastroenteropancreatic neuroendocrine tumours: a meta-analysis.
    Treglia G, Castaldi P, Rindi G, Giordano A, Rufini V.
    Endocrine; 2012 Aug 15; 42(1):80-7. PubMed ID: 22350660
    [Abstract] [Full Text] [Related]

  • 16. Somatostatin-receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors.
    Kwekkeboom DJ, Kam BL, van Essen M, Teunissen JJ, van Eijck CH, Valkema R, de Jong M, de Herder WW, Krenning EP.
    Endocr Relat Cancer; 2010 Mar 15; 17(1):R53-73. PubMed ID: 19995807
    [Abstract] [Full Text] [Related]

  • 17. Diagnostic performance and clinical impact of 18F-AlF-NOTA-octreotide in a large cohort of patients with neuroendocrine neoplasms: A prospective single-center study.
    Hou G, Cheng X, Yang Y, Zhao D, Wang G, Zhao H, Zheng R, Wang X, Chen X, Chi Y, Zhang J.
    Theranostics; 2024 Mar 15; 14(8):3213-3220. PubMed ID: 38855183
    [Abstract] [Full Text] [Related]

  • 18. Clinical applications of Gallium-68.
    Banerjee SR, Pomper MG.
    Appl Radiat Isot; 2013 Jun 15; 76():2-13. PubMed ID: 23522791
    [Abstract] [Full Text] [Related]

  • 19. Gallium-68 PET: a new frontier in receptor cancer imaging.
    Al-Nahhas A, Win Z, Szyszko T, Singh A, Nanni C, Fanti S, Rubello D.
    Anticancer Res; 2007 Jun 15; 27(6B):4087-94. PubMed ID: 18225576
    [Abstract] [Full Text] [Related]

  • 20. The untapped potential of Gallium 68-PET: the next wave of ⁶⁸Ga-agents.
    Smith DL, Breeman WA, Sims-Mourtada J.
    Appl Radiat Isot; 2013 Jun 15; 76():14-23. PubMed ID: 23232184
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.